Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone33-1-81-69-16-00
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.43 million
Profitability
Miscellaneous
Employees161
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Cellectis (NASDAQ:CLLS) Frequently Asked Questions
What is Cellectis' stock symbol?
Cellectis trades on the NASDAQ under the ticker symbol "CLLS."
How were Cellectis' earnings last quarter?
Cellectis SA (NASDAQ:CLLS) released its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.18. The biotechnology company earned $2.93 million during the quarter, compared to analyst estimates of $3.45 million. Cellectis had a negative net margin of 813.06% and a negative return on equity of 21.51%. View Cellectis' Earnings History.
When is Cellectis' next earnings date?
What price target have analysts set for CLLS?
6 equities research analysts have issued twelve-month price targets for Cellectis' shares. Their predictions range from $20.00 to $50.00. On average, they expect Cellectis' share price to reach $34.60 in the next year. This suggests a possible upside of 241.9% from the stock's current price. View Analyst Price Targets for Cellectis.
What is the consensus analysts' recommendation for Cellectis?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.
Has Cellectis been receiving favorable news coverage?
Media coverage about CLLS stock has been trending somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectis earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Cellectis.
Are investors shorting Cellectis?
Cellectis saw a increase in short interest in September. As of September 30th, there was short interest totalling 202,800 shares, an increase of 60.1% from the August 30th total of 126,700 shares. Based on an average trading volume of 114,500 shares, the short-interest ratio is presently 1.8 days. Currently, 0.5% of the company's shares are short sold. View Cellectis' Current Options Chain.
Who are some of Cellectis' key competitors?
Some companies that are related to Cellectis include Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG) and Twist Bioscience (TWST).
What other stocks do shareholders of Cellectis own?
Who are Cellectis' key executives?
Cellectis' management team includes the folowing people:
- Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
- Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
- Mr. Eric Dutang, Chief Financial Officer (Age 45)
- Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
- Mr. Jean Charles Epinat, Chief Technological Officer
When did Cellectis IPO?
(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.
How do I buy shares of Cellectis?
Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cellectis' stock price today?
One share of CLLS stock can currently be purchased for approximately $10.12.
How big of a company is Cellectis?
Cellectis has a market capitalization of $429.59 million and generates $21.43 million in revenue each year. The biotechnology company earns $-78,690,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Cellectis employs 161 workers across the globe.View Additional Information About Cellectis.
What is Cellectis' official website?
How can I contact Cellectis?
Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]
MarketBeat Community Rating for Cellectis (NASDAQ CLLS)
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
